Since previous studies suggest a significant anti-tumor activity for MDM2 inhibitors in p53-mutated cancer cells [14] and the non-clinical-stage inhibitor Nutlin-3a has been shown to induce apoptosis in TNBC at higher micromolar concentrations [16,17], we aimed to address if novel clinical-stage MDM2 inhibitors that possess an increased pharmacological potency over Nutlin-3a efficiently [26] target cell viability in TNBC. This evidence concerns the gene TP53 and cancer.